Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy

Chronic myelogenous leukemia (CML) is effectively treated with imatinib mesylate (IM), a small molecule inhibitor of the BCR-ABL tyrosine kinase that is expressed in the entire hematopoietic compartment including stem cells (HSC) and progenitors in CML patients. While IM induces disease remission, i...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Abe, Akihiro, Minami, Yosuke, Hayakawa, Fumihiko, Kitamura, Kunio, Nomura, Yuka, Murata, Makoto, Katsumi, Akira, Kiyoi, Hitoshi, Jamieson, Catriona H. M., Wang, Jean Y. J., Naoe, Tomoki
Format: Artigo
Sprog:Inglês
Udgivet: 2008
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2626150/
https://ncbi.nlm.nih.gov/pubmed/19039626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-008-0221-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker